A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma (Q44564587)
Jump to navigation
Jump to search
scientific article published in September 2003
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma |
scientific article published in September 2003 |
Statements
1 reference
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma (English)
1 reference
1 reference
Gabriel N Hortobagyi
1 reference
Edgardo Rivera
1 reference
Massimo Cristofanilli
1 reference
Vicente Valero
1 reference
Melanie Royce
1 reference
Anil Duggal
1 reference
Philippe Colucci
1 reference
Robert DeJager
1 reference
1 September 2003
1 reference
1 reference
Identifiers
1 reference